Drug Profile


Alternative Names: EB-1627; GMX 1777

Latest Information Update: 20 Feb 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator LEO Pharma
  • Developer Gemin X Biotechnologies
  • Class Antineoplastics; Guanidines; Pyridines; Small molecules
  • Mechanism of Action Nicotinamide phosphoribosyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Lymphoma; Solid tumours
  • Discontinued Malignant melanoma

Most Recent Events

  • 17 Aug 2012 Gemin X (now Cephalon) terminates phase I trial in Lymphoma or Solid tumours in USA (NCT00457574)
  • 30 Apr 2011 Gemin X is now a wholly-owned subsidiary of Cephalon
  • 21 Sep 2009 Clinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top